Depression and cardiac disease: epidemiology, mechanisms, and diagnosis

Jeff C Huffman, Christopher M Celano, Scott R Beach, Shweta R Motiwala, James L Januzzi, Jeff C Huffman, Christopher M Celano, Scott R Beach, Shweta R Motiwala, James L Januzzi

Abstract

In patients with cardiovascular disease (CVD), depression is common, persistent, and associated with worse health-related quality of life, recurrent cardiac events, and mortality. Both physiological and behavioral factors-including endothelial dysfunction, platelet abnormalities, inflammation, autonomic nervous system dysfunction, and reduced engagement in health-promoting activities-may link depression with adverse cardiac outcomes. Because of the potential impact of depression on quality of life and cardiac outcomes, the American Heart Association has recommended routine depression screening of all cardiac patients with the 2- and 9-item Patient Health Questionnaires. However, despite the availability of these easy-to-use screening tools and effective treatments, depression is underrecognized and undertreated in patients with CVD. In this paper, we review the literature on epidemiology, phenomenology, comorbid conditions, and risk factors for depression in cardiac disease. We outline the associations between depression and cardiac outcomes, as well as the mechanisms that may mediate these links. Finally, we discuss the evidence for and against routine depression screening in patients with CVD and make specific recommendations for when and how to assess for depression in this high-risk population.

Figures

Figure 1
Figure 1
Mechanisms by which depression may impact cardiac outcomes.

References

    1. Mavrides N, Nemeroff C. Treatment of depression in cardiovascular disease. Depression and Anxiety. 2013
    1. Celano CM, Huffman JC. Depression and cardiac disease: a review. Cardiology in Review. 2011;19(3):130–142.
    1. Carney RM, Freedland KE. Depression in patients with coronary heart disease. The American Journal of Medicine. 2008;121(11, supplement 1):S20–S27.
    1. Lespérance F, Frasure-Smith N, Juneau M, Théroux P. Depression and 1-year prognosis in unstable angina. Archives of Internal Medicine. 2000;160(9):1354–1360.
    1. Schleifer SJ, Macari-Hinson MM, Coyle DA, et al. The nature and course of depression following myocardial infarction. Archives of Internal Medicine. 1989;149(8):1785–1789.
    1. Thombs BD, de Jonge P, Coyne JC, et al. Depression screening and patient outcomes in cardiovascular care: a systematic review. The Journal of the American Medical Association. 2008;300(18):2161–2171.
    1. Thombs BD, Bass EB, Ford DE, et al. Prevalence of depression in survivors of acute myocardial infarction: review of the evidence. Journal of General Internal Medicine. 2006;21(1):30–38.
    1. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the national comorbidity survey replication (NCS-R) The Journal of the American Medical Association. 2003;289(23):3095–3105.
    1. Hedayati SS, Bosworth HB, Kuchibhatla M, Kimmel PL, Szczech LA. The predictive value of self-report scales compared with physician diagnosis of depression in hemodialysis patients. Kidney International. 2006;69(9):1662–1668.
    1. Snyderman D, Wynn D. Depression in cancer patients. Primary Care—Clinics in Office Practice. 2009;36(4):703–719.
    1. Magyar-Russell G, Thombs BD, Cai JX, et al. The prevalence of anxiety and depression in adults with implantable cardioverter defibrillators: a systematic review. Journal of Psychosomatic Research. 2011;71(4):223–231.
    1. Rutledge T, Reis VA, Linke SE, Greenberg BH, Mills PJ. Depression in heart failure. A meta-analytic review of prevalence, intervention effects, and associations with clinical outcomes. Journal of the American College of Cardiology. 2006;48(8):1527–1537.
    1. McCabe PJ. Psychological distress in patients diagnosed with atrial fibrillation: the state of the science. Journal of Cardiovascular Nursing. 2010;25(1):40–51.
    1. Tully PJ, Baker RA. Depression, anxiety, and cardiac morbidity outcomes after coronary artery bypass surgery: a contemporary and practical review. Journal of Geriatric Cardiology. 2012;9(2):197–208.
    1. Glassman AH, Bigger JT, Gaffney M, Shapiro PA, Swenson JR. Onset of major depression associated with acute coronary syndromes: relationship of onset, major depressive disorder history, and episode severity to sertraline benefit. Archives of General Psychiatry. 2006;63(3):283–288.
    1. Lespérance F, Frasure-Smith N, Koszycki D, et al. Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy (CREATE) trial. The Journal of the American Medical Association. 2007;297(4):367–379.
    1. Huffman JC, Mastromauro CA, Sowden GL, Wittmann C, Rodman R, Januzzi JL. A collaborative care depression management program for cardiac inpatients: depression characteristics and in-hospital outcomes. Psychosomatics. 2011;52(1):26–33.
    1. Hance M, Carney RM, Freedland KE, Skala J. Depression in patients with coronary heart disease: a 12-month follow-up. General Hospital Psychiatry. 1996;18(1):61–65.
    1. Martens EJ, Smith ORF, Winter J, Denollet J, Pedersen SS. Cardiac history, prior depression and personality predict course of depressive symptoms after myocardial infarction. Psychological Medicine. 2008;38(2):257–264.
    1. Kaptein KI, de Jonge P, van den Brink RHS, Korf J. Course of depressive symptoms after myocardial infarction and cardiac prognosis: a latent class analysis. Psychosomatic Medicine. 2006;68(5):662–668.
    1. Koenig HG. Depression outcome in inpatients with congestive heart failure. Archives of Internal Medicine. 2006;166(9):991–996.
    1. Suzuki T, Shiga T, Kuwahara K, et al. Prevalence and persistence of depression in patients with implantable cardioverter defibrillator: a 2-year longitudinal study. Pacing and Clinical Electrophysiology. 2010;33(12):1455–1461.
    1. Kroenke K, Spitzer RL, Williams JBW. The patient health questionnaire-2: validity of a two-item depression screener. Medical Care. 2003;41(11):1284–1292.
    1. Kroenke K, Spitzer RL, Williams JBW. The PHQ-9: validity of a brief depression severity measure. Journal of General Internal Medicine. 2001;16(9):606–613.
    1. Shankman SA, Nadelson J, McGowan SK, Sovari AA, Vidovich MI. The predictive power of depression screening procedures for veterans with coronary artery disease. Journal of Vascular Health and Risk Management. 2012;8:233–238.
    1. Caro MA, Sowden GL, Mastromauro CA, et al. Risk factors for positive depression screens in hospitalized cardiac patients. Journal of Cardiology. 2012;60(1):72–77.
    1. Mallik S, Spertus JA, Reid KJ, et al. Depressive symptoms after acute myocardial infarction: evidence for highest rates in younger women. Archives of Internal Medicine. 2006;166(8):876–883.
    1. Strik JJMH, Lousberg R, Cheriex EC, Honig A. One year cumulative incidence of depression following myocardial infarction and impact on cardiac outcome. Journal of Psychosomatic Research. 2004;56(1):59–66.
    1. Shanmugasegaram S, Russell KL, Kovacs AH, Stewart DE, Grace SL. Gender and sex differences in prevalence of major depression in coronary artery disease patients: a meta-analysis. Maturitas. 2012;73(4):305–311.
    1. Busch AM, Borrelli B, Leventhal AM. The relationship between smoking and depression post-acute coronary syndrome. Current Cardiovascular Risk Reports. 2012;5(6):510–518.
    1. Spijkerman TA, van den Brink RHS, Jansen JHC, Crijns HJGM, Ormel J. Who is at risk of post-MI depressive symptoms? Journal of Psychosomatic Research. 2005;58(5):425–432.
    1. Frazier L, Yu E, Sanner J, et al. Gender differences in self-reported symptoms of depression among patients with acute coronary syndrome. Nursing Research and Practice. 2012;2012:5 pages.109251
    1. Pena FM, Modenesi Rde F, Piraciaba MC, et al. Prevalence and variables predictive of depressive symptoms in patients hospitalized for heart failure. Cardiology Journal. 2011;18(1):18–25.
    1. Sin MK. Personal characteristics predictive of depressive symptoms in Hispanics with heart failure. Issues in Mental Health Nursing. 2012;33(8):522–527.
    1. Lossnitzer N, Herzog W, Stork S, et al. Incidence rates and predictors of major and minor depression in patients with heart failure. International Journal of Cardiology. 2012
    1. Dunkel A, Kendel F, Lehmkuhl E, et al. Predictors of preoperative depressive risk in patients undergoing coronary artery bypass graft surgery. Clinical Research in Cardiology. 2009;98(10):643–650.
    1. McKenzie LH, Simpson J, Stewart M. A systematic review of pre-operative predictors of post-operative depression and anxiety in individuals who have undergone coronary artery bypass graft surgery. Psychology, Health and Medicine. 2010;15(1):74–93.
    1. Freedenberg V, Thomas SA, Friedmann E. Anxiety and depression in implanted cardioverter-defibrillator recipients and heart failure: a review. Heart Failure Clinics. 2011;7(1):59–68.
    1. Doering LV, Moser DK, Riegel B, et al. Persistent comorbid symptoms of depression and anxiety predict mortality in heart disease. International Journal of Cardiology. 2010;145(2):188–192.
    1. Denollet J, Strik JJ, Lousberg R, Honig A. Recognizing increased risk of depressive comorbidity after myocardial infarction: looking for 4 symptoms of anxiety-depression. Psychotherapy and Psychosomatics. 2006;75(6):346–352.
    1. Frasure-Smith N, Lespérance F. Depression and anxiety as predictors of 2-year cardiac events in patients with stable coronary artery disease. Archives of General Psychiatry. 2008;65(1):62–71.
    1. de Schutter A, Lavie CJ, Milani RV. Relative importance of comorbid psychological symptoms in patients with depressive symptoms following phase II cardiac rehabilitation. Postgraduate Medicine. 2011;123(6):72–78.
    1. Bankier B, Januzzi JL, Littman AB. The high prevalence of multiple psychiatric disorders in stable outpatients with coronary heart disease. Psychosomatic Medicine. 2004;66(5):645–650.
    1. Martens EJ, de Jonge P, Na B, Cohen BE, Lett H, Whooley MA. Scared to death? Generalized anxiety disorder and cardiovascular events in patients with stable coronary heart disease: the heart and soul study. Archives of General Psychiatry. 2010;67(7):750–758.
    1. Parker G, Hyett M, Hadzi-Pavlovic D, Brotchie H, Walsh W. GAD is good? Generalized anxiety disorder predicts a superior five-year outcome following an acute coronary syndrome. Psychiatry Research. 2011;188(3):383–389.
    1. Dao TK, Chu D, Springer J, et al. Clinical depression, posttraumatic stress disorder, and comorbid depression and posttraumatic stress disorder as risk factors for in-hospital mortality after coronary artery bypass grafting surgery. Journal of Thoracic and Cardiovascular Surgery. 2010;140(3):606–610.
    1. Ladwig KH, Baumert J, Marten-Mittag B, Kolb C, Zrenner B, Schmitt C. Posttraumatic stress symptoms and predicted mortality in patients with implantable cardioverter-defibrillators: results from the prospective living with an implanted cardioverter-defibrillator study. Archives of General Psychiatry. 2008;65(11):1324–1330.
    1. von Känel R, Baumert J, Kolb C, Cho EYN, Ladwig KH. Chronic posttraumatic stress and its predictors in patients living with an implantable cardioverter defibrillator. Journal of Affective Disorders. 2011;131(1-3):344–352.
    1. Sears SF, Hauf JD, Kirian K, Hazelton G, Conti JB. Posttraumatic stress and the implantable cardioverter-defibrillator patient: what the electrophysiologist needs to know. Circulation: Arrhythmia and Electrophysiology. 2011;4(2):242–250.
    1. Phillips AC, Batty GD, Gale CR, et al. Generalized anxiety disorder, major depressive disorder, and their comorbidity as predictors of all-cause and cardiovascular mortality: the Vietnam experience study. Psychosomatic Medicine. 2009;71(4):395–403.
    1. Roest AM, Zuidersma M, de Jonge P. Myocardial infarction and generalised anxiety disorder: 10-year follow-up. The British Journal of Psychiatry. 2012;200(4):324–329.
    1. Kroenke K, Spitzer RL, Williams JBW, Löwe B. An ultra-brief screening scale for anxiety and depression: the PHQ-4. Psychosomatics. 2009;50(6):613–621.
    1. Spitzer RL, Kroenke K, Williams JBW, Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Archives of Internal Medicine. 2006;166(10):1092–1097.
    1. Pizzi C, Manzoli L, Mancini S, Bedetti G, Fontana F, Costa GM. Autonomic nervous system, inflammation and preclinical carotid atherosclerosis in depressed subjects with coronary risk factors. Atherosclerosis. 2010;212(1):292–298.
    1. Ford DE, Mead LA, Chang PP, Cooper-Patrick L, Wang NY, Klag MJ. Depression is a risk factor for coronary artery disease in men: the precursors study. Archives of Internal Medicine. 1998;158(13):1422–1426.
    1. Wulsin LR, Singal BM. Do depressive symptoms increase the risk for the onset of coronary disease? A systematic quantitative review. Psychosomatic Medicine. 2003;65(2):201–210.
    1. Carney RM, Rich MW, Freedland KE, et al. Major depressive disorder predicts cardiac events in patients with coronary artery disease. Psychosomatic Medicine. 1988;50(6):627–633.
    1. Kop WJ, Stein PK, Tracy RP, Barzilay JI, Schulz R, Gottdiener JS. Autonomic nervous system dysfunction and inflammation contribute to the increased cardiovascular mortality risk associated with depression. Psychosomatic Medicine. 2010;72(7):626–635.
    1. van der Kooy K, van Hout H, Marwijk H, Marten H, Stehouwer C, Beekman A. Depression and the risk for cardiovascular diseases: systematic review and meta analysis. International Journal of Geriatric Psychiatry. 2007;22(7):613–626.
    1. van Melle JP, de Jonge P, Spijkerman TA, et al. Prognostic association of depression following myocardial infarction with mortality and cardiovascular events: a meta-analysis. Psychosomatic Medicine. 2004;66(6):814–822.
    1. Frasure-Smith N, Lesperance F, Talajic M. Depression and 18-month prognosis after myocardial infarction. Circulation. 1995;91(4):999–1005.
    1. Whang W, Kubzansky LD, Kawachi I, et al. Depression and risk of sudden cardiac death and coronary heart disease in women. Results from the nurses’ health study. Journal of the American College of Cardiology. 2009;53(11):950–958.
    1. Frasure-Smith N, Lesperance F, Talajic M. Depression following myocardial infarction: impact on 6-month survival. The Journal of the American Medical Association. 1993;270(15):1819–1825.
    1. Barth J, Schumacher M, Herrmann-Lingen C. Depression as a risk factor for mortality in patients with coronary heart disease: a meta-analysis. Psychosomatic Medicine. 2004;66(6):802–813.
    1. Myers V, Gerber Y, Benyamini Y, Goldbourt U, Drory Y. Post-myocardial infarction depression: increased hospital admissions and reduced adoption of secondary prevention measures—a longitudinal study. Journal of Psychosomatic Research. 2012;72(1):5–10.
    1. Ziegelstein RC, Fauerbach JA, Stevens SS, Romanelli J, Richter DP, Bush DE. Patients with depression are less likely to follow recommendations to reduce cardiac risk during recovery from a myocardial infarction. Archives of Internal Medicine. 2000;160(12):1818–1823.
    1. Kurdyak PA, Gnam WH, Goering P, Chong A, Alter DA. The relationship between depressive symptoms, health service consumption, and prognosis after acute myocardial infarction: a prospective cohort study. BMC Health Services Research. 2008;8(article 200)
    1. Reese RL, Freedland KE, Steinmeyer BC, Rich MW, Rackley JW, Carney RM. Depression and rehospitalization following acute myocardial infarction. Circulation: Cardiovascular Quality and Outcomes. 2011;4(6):626–633.
    1. Leung YW, Flora DB, Gravely S, Irvine J, Carney RM, Grace SL. The impact of premorbid and postmorbid depression onset on mortality and cardiac morbidity among patients with coronary heart disease: meta-analysis. Psychosomatic Medicine. 2012;74(8):786–801.
    1. Freedland KE, Carney RM, Rich MW. Effect of depression on prognosis in heart failure. Heart Failure Clinics. 2011;7(1):11–21.
    1. Lange HW, Herrmann-Lingen C. Depressive symptoms predict recurrence of atrial fibrillation after cardioversion. Journal of Psychosomatic Research. 2007;63(5):509–513.
    1. Frasure-Smith N, Lespérance F, Habra M, et al. Elevated depression symptoms predict long-term cardiovascular mortality in patients with atrial fibrillation and heart failure. Circulation. 2009;120(2):134–140.
    1. Beresnevait M, Benetis R, Taylor GJ, Jurnien K, Kinduris Š, Barauskien V. Depression predicts perioperative outcomes following coronary artery bypass graft surgery. Scandinavian Cardiovascular Journal. 2010;44(5):289–294.
    1. Morone NE, Weiner DK, Belnap BH, et al. The impact of pain and depression on recovery after coronary artery bypass grafting. Psychosomatic Medicine. 2010;72(7):620–625.
    1. Burg MM, Benedetto MC, Rosenberg R, Soufer R. Presurgical depression predicts medical morbidity 6 months after coronary artery bypass graft surgery. Psychosomatic Medicine. 2003;65(1):111–118.
    1. Goyal TM, Idler EL, Krause TJ, Contrada RJ. Quality of life following cardiac surgery: impact of the severity and course of depressive symptoms. Psychosomatic Medicine. 2005;67(5):759–765.
    1. Wellenius GA, Mukamal KJ, Kulshreshtha A, Asonganyi S, Mittleman MA. Depressive symptoms and the risk of atherosclerotic progression among patients with coronary artery bypass grafts. Circulation. 2008;117(18):2313–2319.
    1. Burg MM, Benedetto MC, Soufer R. Depressive symptoms and mortality two years after coronary artery bypass graft surgery (CABG) in men. Psychosomatic Medicine. 2003;65(4):508–510.
    1. Blumenthal JA, Lett HS, Babyak MA, et al. Depression as a risk factor for mortality after coronary artery bypass surgery. The Lancet. 2003;362(9384):604–609.
    1. van den Broek KC, Tekle FB, Habibovic M, Alings M, van der Voort PH, Denollet J. Emotional distress, positive affect, and mortality in patients with an implantable cardioverter defibrillator. International Journal of Cardiology. 2011
    1. de Jonge P, Honig A, van Melle JP, et al. Nonresponse to treatment for depression following myocardial infarction: association with subsequent cardiac events. The American Journal of Psychiatry. 2007;164(9):1371–1378.
    1. Carney RM, Blumenthal JA, Freedland KE, et al. Depression and late mortality after myocardial infarction in the enhancing recovery in coronary heart disease (ENRICHD) study. Psychosomatic Medicine. 2004;66(4):466–474.
    1. Roest AM, Martens EJ, Denollet J, de Jonge P. Prognostic association of anxiety post myocardial infarction with mortality and new cardiac events: a meta-analysis. Psychosomatic Medicine. 2010;72(6):563–569.
    1. Howland RH, Wilson MG, Kornstein SG, et al. Factors predicting reduced antidepressant response: experience with the SNRI duloxetine in patients with major depression. Annals of Clinical Psychiatry. 2008;20(4):209–218.
    1. Rush AJ, Wisniewski SR, Warden D, et al. Selecting among second-step antidepressant medication monotherapies: predictive value of clinical, demographic, or first-step treatment features. Archives of General Psychiatry. 2008;65(8):870–880.
    1. Celano CM, Mastromauro CA, Lenihan EC, Januzzi JL, Rollman BL, Huffman JC. Association of baseline anxiety with depression persistence at 6 months in patients with acute cardiac illness. Psychosomatic Medicine. 2012;74(1):93–99.
    1. Davidson KW, Burg MM, Kronish IM, et al. Association of anhedonia with recurrent major adverse cardiac events and mortality 1 year after acute coronary syndrome. Archives of General Psychiatry. 2010;67(5):480–488.
    1. Doyle F, Conroy R, McGee H. Differential predictive value of depressive versus anxiety symptoms in the prediction of 8-year mortality after acute coronary syndrome. Psychosomatic Medicine. 2012;74(7):711–716.
    1. Damen NL, Pelle AJ, Boersma E, Serruys PW, van Domburg RT, Pedersen SS. Reduced positive affect (anhedonia) is independently associated with 7-year mortality in patients treated with percutaneous coronary intervention: results from the RESEARCH registry. European Journal of Preventive Cardiology. 2013;20(1):127–134.
    1. Coyne JC, de Voogd JN. Are we witnessing the decline effect in the type D personality literature? What can be learned? Journal of Psychosomatic Research. 2012;73(6):401–407.
    1. Moyer CF, Sajuthi D, Tulli H, Williams JK. Synthesis of IL-1 α and IL-1 β by arterial cells in atherosclerosis. The American Journal of Pathology. 1991;138(4):951–960.
    1. Ross R. Atherosclerosis–an inflammatory disease. The New England Journal of Medicine. 1999;340(2):115–126.
    1. Hasper D, Hummel M, Kleber FX, Reindl I, Volk HD. Systemic inflammation in patients with heart failure. European Heart Journal. 1998;19(5):761–765.
    1. Kania G, Blyszczuk P, Eriksson U. Mechanisms of cardiac fibrosis in inflammatory heart disease. Trends in Cardiovascular Medicine. 2009;19(8):247–252.
    1. Heeschen C, Hamm CW, Bruemmer J, Simoons ML. Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis. Journal of the American College of Cardiology. 2000;35(6):1535–1542.
    1. Kell R, Haunstetter A, Dengler TJ, Zugck C, Kübler W, Haass M. Do cytokines enable risk stratification to be improved in NYHA functional class III patients? Comparison with other potential predictors of prognosis. European Heart Journal. 2002;23(1):70–78.
    1. Jimenez JA, Mills PJ. Neuroimmune mechanisms of depression in heart failure. Methods in Molecular Biology. 2012;934:165–182.
    1. Kop WJ, Synowski SJ, Gottlieb SS. Depression in heart failure: biobehavioral mechanisms. Heart Failure Clinics. 2011;7(1):23–38.
    1. Howren MB, Lamkin DM, Suls J. Associations of depression with c-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosomatic Medicine. 2009;71(2):171–186.
    1. Miller AH, Maletic V, Raison CL. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biological Psychiatry. 2009;65(9):732–741.
    1. Kop WJ, Kuhl EA, Barasch E, Jenny NS, Gottlieb SS, Gottdiener JS. Association between depressive symptoms and fibrosis markers: the cardiovascular health study. Brain, Behavior, and Immunity. 2010;24(2):229–235.
    1. Vaccarino V, Johnson BD, Sheps DS, et al. Depression, inflammation, and incident cardiovascular disease in women with suspected coronary ischemia. The national heart, lung, and blood institute-sponsored WISE study. Journal of the American College of Cardiology. 2007;50(21):2044–2050.
    1. Katafuchi T, Kondo T, Take S, Yoshimura M. Brain cytokines and the 5-HT system during poly I:C-induced fatigue. Annals of the New York Academy of Sciences. 2006;1088:230–237.
    1. Katafuchi T, Kondo T, Take S, Yoshimura M. Enhanced expression of brain interferon-α and serotonin transporter in immunologically induced fatigue in rats. European Journal of Neuroscience. 2005;22(11):2817–2826.
    1. Wirleitner B, Rudzite V, Neurauter G, et al. Immune activation and degradation of tryptophan in coronary heart disease. European Journal of Clinical Investigation. 2003;33(7):550–554.
    1. Skop BP, Brown TM. Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors. Psychosomatics. 1996;37(1):12–16.
    1. Miyata K, Shimokawa H, Higo T, et al. Sarpogrelate, a selective 5-HT(2A) serotonergic receptor antagonist, inhibits serotonin-induced coronary artery spasm in a porcine model. Journal of Cardiovascular Pharmacology. 2000;35(2):294–301.
    1. Verma S, Wang CH, Li SH, et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation. 2002;106(8):913–919.
    1. Fischer D, Rossa S, Landmesser U, et al. Endothelial dysfunction in patients with chronic heart failure is independently associated with increased incidence of hospitalization, cardiac transplantation, or death. European Heart Journal. 2005;26(1):65–69.
    1. Katz SD, Hryniewicz K, Hriljac I, et al. Vascular endothelial dysfunction and mortality risk in patients with chronic heart failure. Circulation. 2005;111(3):310–314.
    1. Cooper DC, Milic MS, Tafur JR, et al. Adverse impact of mood on flow-mediated dilation. Psychosomatic Medicine. 2010;72(2):122–127.
    1. Tomfohr LM, Murphy MLM, Miller GE, Puterman E. Multiwave associations between depressive symptoms and endothelial function in adolescent and young adult females. Psychosomatic Medicine. 2011;73(6):456–461.
    1. Pizzi C, Manzoli L, Mancini S, Costa GM. Analysis of potential predictors of depression among coronary heart disease risk factors including heart rate variability, markers of inflammation, and endothelial function. European Heart Journal. 2008;29(9):1110–1117.
    1. Sherwood A, Hinderliter AL, Watkins LL, Waugh RA, Blumenthal JA. Impaired endothelial function in coronary heart disease patients with depressive symptomatology. Journal of the American College of Cardiology. 2005;46(4):656–659.
    1. Pizzi C, Mancini S, Angeloni L, Fontana F, Manzoli L, Costa GM. Effects of selective serotonin reuptake inhibitor therapy on endothelial function and inflammatory markers in patients with coronary heart disease. Clinical Pharmacology and Therapeutics. 2009;86(5):527–532.
    1. Vikenes K, Farstad M, Nordrehaug JE. Serotonin is associated with coronary artery disease and cardiac events. Circulation. 1999;100(5):483–489.
    1. Serebruany VL, Suckow RF, Cooper TB, et al. Relationship between release of platelet/endothelial biomarkers and plasma levels of sertraline and N-desmethylsertraline in acute coronary syndrome patients receiving SSRI treatment for depression. The American Journal of Psychiatry. 2005;162(6):1165–1170.
    1. Serebruany VL, Gurbel PA, O’Connor CM. Platelet inhibition by sertraline and N-desmethylsertraline: a possible missing link between depression, coronary events, and mortality benefits of selective serotonin reuptake inhibitors. Pharmacological Research. 2001;43(5):453–462.
    1. Schins A, Hamulyák K, Scharpé S, et al. Whole blood serotonin and platelet activation in depressed post-myocardial infarction patients. Life Sciences. 2004;76(6):637–650.
    1. Arora RC, Meltzer HY. Increased serotonin2 (5-HT2) receptor binding as measured by 3H-lysergic acid diethylamide (3H-LSD) in the blood platelets of depressed patients. Life Sciences. 1989;44(11):725–734.
    1. Hrdina PD, Bakish D, Ravindran A, Chudzik J, Cavazzoni P, Lapierre YD. Platelet serotonergic indices in major depression: up-regulation of 5-HT(2A) receptors unchanged by antidepressant treatment. Psychiatry Research. 1997;66(2-3):73–85.
    1. Nemeroff CB, Knight DL, Franks J, Craighead WE, Krishnan KRR. Further studies on platelet serotonin transporter binding in depression. The American Journal of Psychiatry. 1994;151(11):1623–1625.
    1. Kuijpers PMJC, Hamulyak K, Strik JJMH, Wellens HJJ, Honig A. β-thromboglobulin and platelet factor 4 levels in post-myocardial infarction patients with major depression. Psychiatry Research. 2002;109(2):207–210.
    1. Serebruany VL, Glassman AH, Malinin AI, et al. Enhanced platelet/endothelial activation in depressed patients with acute coronary syndromes: evidence from recent clinical trials. Blood Coagulation and Fibrinolysis. 2003;14(6):563–567.
    1. Gehi A, Musselman D, Otte C, Royster EB, Ali S, Whooley MA. Depression and platelet activation in outpatients with stable coronary heart disease: findings from the heart and soul study. Psychiatry Research. 2010;175(3):200–204.
    1. Anand IS, Fisher LD, Chiang YT, et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan heart failure trial (Val-HeFT) Circulation. 2003;107(9):1278–1283.
    1. Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. The New England Journal of Medicine. 1984;311(13):819–823.
    1. Gold PW, Wong ML, Goldstein DS, et al. Cardiac implications of increased arterial entry and reversible 24-h central and peripheral norepinephrine levels in melancholia. Proceedings of the National Academy of Sciences of the United States of America. 2005;102(23):8303–8308.
    1. Frenneaux MP. Autonomic changes in patients with heart failure and in post-myocardial infarction patients. Heart. 2004;90(11):1248–1255.
    1. La Rovere MT, Pinna GD, Hohnloser SH, et al. Barorefiex sensitivity and heart rate variability in the identification of patients at risk for life-threatening arrhythmias: implications for clinical trials. Circulation. 2001;103(16):2072–2077.
    1. Buccelletti F, Gilardi E, Scaini E, et al. Heart rate variability and myocardial infarction: systematic literature review and metanalysis. European Review for Medical and Pharmacological Sciences. 2009;13(4):299–307.
    1. Schwartz PJ, Vanoli E, Stramba-Badiale M, de Ferrari GM, Billman GE, Foreman RD. Autonomic mechanisms and sudden death: new insights from analysis of baroreceptor reflexes in conscious dogs with and without a myocardial infarction. Circulation. 1988;78(4 I):969–979.
    1. Kemp AH, Quintana DS, Gray MA, Felmingham KL, Brown K, Gatt JM. Impact of depression and antidepressant treatment on heart rate variability: a review and meta-analysis. Biological Psychiatry. 2010;67(11):1067–1074.
    1. Glassman AH, Bigger JT, Gaffney M, van Zyl LT. Heart rate variability in acute coronary syndrome patients with major depression: influence of sertraline and mood improvement. Archives of General Psychiatry. 2007;64(9):1025–1031.
    1. Dao TK, Youssef NA, Gopaldas RR, et al. Autonomic cardiovascular dysregulation as a potential mechanism underlying depression and coronary artery bypass grafting surgery outcomes. Journal of Cardiothoracic Surgery. 2010;5(1, article 36)
    1. Hashimoto K. Brain-derived neurotrophic factor as a biomarker for mood disorders: an historical overview and future directions. Psychiatry and Clinical Neurosciences. 2010;64(4):341–357.
    1. Castrén E, Rantamäki T. The role of BDNF and its receptors in depression and antidepressant drug action: reactivation of developmental plasticity. Developmental Neurobiology. 2010;70(5):289–297.
    1. Molendijk ML, Bus BA, Spinhoven P, et al. Serum levels of brain-derived neurotrophic factor in major depressive disorder: state-trait issues, clinical features and pharmacological treatment. Molecular Psychiatry. 2011;16(11):1088–1095.
    1. Ohira K, Takeuchi R, Shoji H, Miyakawa T. Fluoxetine-iduced cortical adult neurogenesis. Neuropsychopharmacology. 2013
    1. Kim H, Li Q, Hempstead BL, Madri JA. Paracrine and autocrine functions of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) in brain-derived endothelial cells. The Journal of Biological Chemistry. 2004;279(32):33538–33546.
    1. Okada S, Yokoyama M, Toko H, et al. Brain-derived neurotrophic factor protects against cardiac dysfunction after myocardial infarction via a central nervous system-mediated pathway. Arteriosclerosis, Thrombosis, and Vascular Biology. 2012;32(8):1902–1909.
    1. Hashimoto K. Sigma-1 receptor chaperone and brain-derived neurotrophic factor: emerging links between cardiovascular disease and depression. Progress in Neurobiology. 2013;100:15–29.
    1. Sabino V, Cottone P, Parylak SL, Steardo L, Zorrilla EP. Sigma-1 receptor knockout mice display a depressive-like phenotype. Behavioural Brain Research. 2009;198(2):472–476.
    1. Maurice T, Su TP. The pharmacology of sigma-1 receptors. Pharmacology and Therapeutics. 2009;124(2):195–206.
    1. Ito K, Hirooka Y, Matsukawa R, Nakano M, Sunagawa K. Decreased brain sigma-1 receptor contributes to the relationship between heart failure and depression. Cardiovascular Research. 2012;93(1):33–40.
    1. Kunugi H, Hori H, Adachi N, Numakawa T. Interface between hypothalamic-pituitary-adrenal axis and brain-derived neurotrophic factor in depression. Psychiatry and Clinical Neurosciences. 2010;64(5):447–459.
    1. Bauer LK, Caro MA, Beach SR, et al. Effects of depression and anxiety improvement on adherence to medication and health behaviors in recently hospitalized cardiac patients. The American Journal of Cardiology. 2012;109(9):1266–1271.
    1. Whooley MA, de Jonge P, Vittinghoff E, et al. Depressive symptoms, health behaviors, and risk of cardiovascular events in patients with coronary heart disease. The Journal of the American Medical Association. 2008;300(20):2379–2388.
    1. May HT, Sheng X, Catinella AP, Horne BD, Carlquist JF, Joy E. Antilipidemic adherence post-coronary artery disease diagnosis among those with and without an ICD-9 diagnosis of depression. Journal of Psychosomatic Research. 2010;69(2):169–174.
    1. Casey E, Hughes JW, Waechter D, Josephson R, Rosneck J. Depression predicts failure to complete phase-II cardiac rehabilitation. Journal of Behavioral Medicine. 2008;31(5):421–431.
    1. McGrady A, McGinnis R, Badenhop D, Bentle M, Rajput M. Effects of depression and anxiety on adherence to cardiac rehabilitation. Journal of Cardiopulmonary Rehabilitation and Prevention. 2009;29(6):358–364.
    1. Huffman JC, Smith FA, Fricchione GL, Januzzi JL, Nadelman S, Pirl WF. Depression and failure of cholesterol lowering after acute myocardial infarction. Primary Care Companion to the Journal of Clinical Psychiatry. 2010;12(1)PCC.08m00766
    1. Gehi AK, Ali S, Na B, Whooley MA. Self-reported medication adherence and cardiovascular events in patients with stable coronary heart disease: the heart and soul study. Archives of Internal Medicine. 2007;167(16):1798–1803.
    1. Wessel TR, Arant CB, Olson MB, et al. Relationship of physical fitness versus body mass index with coronary artery disease and cardiovascular events in women. The Journal of the American Medical Association. 2004;292(10):1179–1187.
    1. Huffman JC, Smith FA, Blais MA, Beiser ME, Januzzi JL, Fricchione GL. Recognition and treatment of depression and anxiety in patients with acute myocardial infarction. The American Journal of Cardiology. 2006;98(3):319–324.
    1. Ziegelstein RC, Kim SY, Kao D, et al. Can doctors and nurses recognize depression in patients hospitalized with an acute myocardial infarction in the absence of formal screening? Psychosomatic Medicine. 2005;67(3):393–397.
    1. Lichtman JH, Bigger JT, Jr., Blumenthal JA, et al. Depression and coronary heart disease: recommendations for screening, referral, and treatment—a science advisory from the American heart association prevention committee of the council on cardiovascular nursing, council on clinical cardiology, council on epidemiology and prevention, and interdisciplinary council on quality of care and outcomes research. Circulation. 2008;118(17):1768–1775.
    1. Elderon L, Smolderen KG, Na B, Whooley MA. Accuracy and prognostic value of American heart association: recommended depression screening in patients with coronary heart disease: data from the heart and soul study. Circulation: Cardiovascular Quality and Outcomes. 2011;4(5):533–540.
    1. Rollman BL, Belnap BH, Mazumdar S, et al. A positive 2-item patient health questionnaire depression screen among hospitalized heart failure patients is associated with elevated 12-month mortality. Journal of Cardiac Failure. 2012;18(3):238–245.
    1. Thombs BD, Ziegelstein RC, Whooley MA. Optimizing detection of major depression among patients with coronary artery disease using the patient health questionnaire: data from the heart and soul study. Journal of General Internal Medicine. 2008;23(12):2014–2017.
    1. Sowden G, Mastromauro CA, Januzzi JL, Fricchione GL, Huffman JC. Detection of depression in cardiac inpatients: feasibility and results of systematic screening. The American Heart Journal. 2010;159(5):780–787.
    1. Smolderen KG, Buchanan DM, Amin AA, et al. Real-world lessons from the implementation of a depression screening protocol in acute myocardial infarction patients implications for the american heart association depression screening advisory. Circulation: Cardiovascular Quality and Outcomes. 2011;4(3):283–292.
    1. Ziegelstein RC, Thombs BD, Coyne JC, de Jonge P. Routine screening for depression in patients with coronary heart disease. Never mind. Journal of the American College of Cardiology. 2009;54(10):886–890.
    1. Davidson KW, Rieckmann N, Clemow L, et al. Enhanced depression care for patients with acute coronary syndrome and persistent depressive symptoms: coronary psychosocial evaluation studies randomized controlled trial. Archives of Internal Medicine. 2010;170(7):600–608.
    1. Huffman JC, Mastromauro CA, Sowden G, Fricchione GL, Healy BC, Januzzi JL. Impact of a depression care management program for hospitalized cardiac patients. Circulation: Cardiovascular Quality and Outcomes. 2011;4(2):198–205.
    1. Katon WJ, Lin EHB, Korff MV, et al. Collaborative care for patients with depression and chronic illnesses. The New England Journal of Medicine. 2010;363(27):2611–2620.
    1. Rollman BL, Belnap BH, LeMenager MS, et al. Telephone-delivered collaborative care for treating post-CABG depression: a randomized controlled trial. The Journal of the American Medical Association. 2009;302(19):2095–2103.
    1. Whooley MA. To screen or not to screen? Depression in patients with cardiovascular disease. Journal of the American College of Cardiology. 2009;54(10):891–893.
    1. Glassman AH, O’Connor CM, Califf RM, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. The Journal of the American Medical Association. 2002;288(6):701–709.
    1. O’Connor CM, Jiang W, Kuchibhatla M, et al. Safety and efficacy of sertraline for depression in patients with heart failure: results of the SADHART-CHF (sertraline against depression and heart disease in chronic heart failure) trial. Journal of the American College of Cardiology. 2010;56(9):692–699.
    1. Berkman LF, Blumenthal J, Burg M, et al. Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the enhancing recovery in coronary heart disease patients (ENRICHD) randomized trial. The Journal of the American Medical Association. 2003;289(23):3106–3116.
    1. Freedland KE, Skala JA, Carney RM, et al. Treatment of depression after coronary artery bypass surgery a randomized controlled trial. Archives of General Psychiatry. 2009;66(4):387–396.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever